Skip to content
Film Television Auditions – Lifestyle
Author:
Outlook Therapeutics, Inc.
Outlook Therapeutics Announces Formal Dispute Resolution Request for ONS-5010/LYTENAVA™ (bevacizumab-vikg) Accepted by FDA
April 7, 2026
Outlook Therapeutics Announces Closing of $5.0 Million Public Offering
March 25, 2026
Outlook Therapeutics Announces Pricing of $5.0 Million Public Offering
March 24, 2026
Outlook Therapeutics Announces Proposed Public Offering
March 23, 2026
Outlook Therapeutics Announces New $18.4 Million Non-Convertible Note Financing and Amendment to Existing Convertible Note
March 16, 2026
←
Previous Page
1
2